ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease

Phase 3

Completed

Conditions: Dry Eye Disease

Interventions: Drug: Carboxymethylcellulose Based Eye Drop Formulation A
Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops

First Posted Date: 2012-08-14

Last Posted Date: 2015-09-21

Lead Sponsor: Allergan

Target Recruit Count: 460

Registration Number: NCT01664949

A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine

Phase 3

Completed

Conditions: Migraine Disorders

Interventions: Drug: Placebo (Normal Saline)
Biological: Botulinum toxin type A Dose 1
Biological: Botulinum toxin type A Dose 2

First Posted Date: 2012-08-10

Last Posted Date: 2017-09-05

Lead Sponsor: Allergan

Target Recruit Count: 125

Registration Number: NCT01662492

Locations: 🇺🇸
New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸
Fullerton Neurology and Headache Center, Fullerton, California, United States
🇺🇸
Texas Association of Pediatric Neurology/Road Runner Research, San Antonio, Texas, United States

and more 19 locations

Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)

Phase 3

Completed

Conditions: Macular Edema

Interventions: Drug: 700 μg Dexamethasone
Other: Sham

First Posted Date: 2012-08-09

Last Posted Date: 2019-04-17

Lead Sponsor: Allergan

Target Recruit Count: 262

Registration Number: NCT01660802

A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)

Phase 2

Completed

Conditions: Migraine

Interventions: Drug: Placebo
Drug: MK-1602
Drug: Rescue medication

First Posted Date: 2012-08-06

Last Posted Date: 2016-12-09

Lead Sponsor: Allergan

Target Recruit Count: 195

Registration Number: NCT01657370

A Prospective, Observational Study of Patients With Cervical Dystonia (Dystonie) Treated With OnabotulinumtoxinA

Completed

Conditions: Torticollis

Interventions: Biological: OnabotulinumtoxinA

First Posted Date: 2012-08-02

Last Posted Date: 2017-03-30

Lead Sponsor: Allergan

Target Recruit Count: 62

Registration Number: NCT01655862

Locations: 🇨🇦
Centre Medical Le Mesnil, Quebec, Canada
🇨🇦
CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec, Canada
🇨🇦
Clinique Neuro-Rive Sud, Greenfield Park, Quebec, Canada

and more 5 locations

Chronic Migraine Epidemiology and Outcomes Study

Completed

Conditions: Migraine Disorders

Interventions: Other: No Treatment

First Posted Date: 2012-07-24

Last Posted Date: 2015-01-29

Lead Sponsor: Allergan

Target Recruit Count: 16789

Registration Number: NCT01648530

A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Completed

Conditions: Ocular Hypertension
Glaucoma, Open-Angle

Interventions: Drug: Bimatoprost

First Posted Date: 2012-07-20

Last Posted Date: 2014-06-13

Lead Sponsor: Allergan

Target Recruit Count: 2580

Registration Number: NCT01646151

European New Texture Implant Clinical Experience With Round Breast Implants

Not Applicable

Completed

Conditions: Breast Augmentation

Interventions: Device: New texture round breast implants

First Posted Date: 2012-07-13

Last Posted Date: 2017-11-30

Lead Sponsor: Allergan

Target Recruit Count: 18

Registration Number: NCT01639742

Locations: 🇩🇪
Malteser Krankenhaus, Bonn, Germany
🇸🇪
Akademikliniken 10, Stockholm, Sweden
🇩🇪
Praxisklinik Siepe Friedrichstraße 57, Bonn, Germany

and more 1 locations

European New Texture Implant Clinical Experience With Shaped Breast Implants

Phase 4

Completed

Conditions: Breast Augmentation

Interventions: Device: new texture shaped breast implants

First Posted Date: 2012-07-13

Last Posted Date: 2017-11-30

Lead Sponsor: Allergan

Target Recruit Count: 19

Registration Number: NCT01639755

Locations: 🇸🇪
Klinik 34, Göteburg, Sweden
🇸🇪
Akademikliniken 10, Stockholm, Sweden

A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy

Completed

Conditions: Ocular Hypertension
Glaucoma, Open-Angle

Interventions: Drug: Any Fixed Combination Therapy

First Posted Date: 2012-07-11

Last Posted Date: 2012-09-21

Lead Sponsor: Allergan

Target Recruit Count: 4385

Registration Number: NCT01637246

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy